Amphastar Pharma Q1 2024 Adj EPS $1.04 Beats $0.77 Estimate, Sales $171.800M Miss $174.713M Estimate
Portfolio Pulse from Benzinga Newsdesk
Amphastar Pharma reported Q1 2024 adjusted EPS of $1.04, surpassing the $0.77 estimate, but its sales of $171.800M fell short of the $174.713M forecast. This represents a 22.70% increase in sales compared to the same period last year.
May 08, 2024 | 9:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amphastar Pharma's Q1 2024 earnings exceeded expectations with an EPS of $1.04 against a $0.77 estimate, but sales missed estimates by a small margin.
The significant beat on the EPS estimate is likely to positively impact investor sentiment towards AMPH in the short term, despite the slight miss on sales forecasts. The strong year-over-year sales growth further supports a positive outlook.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100